Inhibition of leukotriene synthesis with MK-886 prevents a rise in blood pressure and reduces noradrenaline-evoked contraction in L-NAME-treated rats

British Journal of Pharmacology

Volumn 140, Issue 1, 2003, Pages 186-194

  Stanke Labesque, Françoise ^a   Hardy, Gaëlle ^a   Caron, Françoise ^a   Cracowski, Jean Luc ^a   Bessard, Germain ^a  

^a University Grenoble Alpes   (France)

Author keywords

5 lipoxygenase; Cysteinyl leukotrienes; Endothelium; Hypertension; Nitric oxide inhibition; Noradrenaline; Rat aorta

Indexed keywords

3 [3 TERT BUTYLTHIO 1 (4 CHLOROBENZYL) 5 ISOPROPYL 2 INDOLYL] 2,2 DIMETHYLPROPIONIC ACID; 6 (4 CARBOXYPHENYLTHIO) 5 HYDROXY 7,9,11,14 ICOSATETRAENOIC ACID; ARACHIDONATE 5 LIPOXYGENASE; LEUKOTRIENE; METHYLCELLULOSE; N(G) NITROARGININE METHYL ESTER; NORADRENALIN; VERLUKAST;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTERY ENDOTHELIUM; ARTICLE; BLOOD PRESSURE REGULATION; CONTROLLED STUDY; ENZYME IMMUNOASSAY; ENZYME SYNTHESIS; HEART CONTRACTION; HYPERTENSION; ISOLATED ARTERY; MALE; MEAN ARTERIAL PRESSURE; MUSCLE ISOMETRIC CONTRACTION; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; RANDOMIZATION; RAT; STATISTICAL SIGNIFICANCE; VASCULAR RING;

ANIMALS; AORTA; BLOOD PRESSURE; DOSE-RESPONSE RELATIONSHIP, DRUG; INDOLES; LEUKOTRIENES; MALE; NG-NITROARGININE METHYL ESTER; NOREPINEPHRINE; RATS; RATS, WISTAR; VASOCONSTRICTION;

EID: 0141618426     PISSN: 00071188     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.bjp.0705405     Document Type: Article

References (33)

1. BUCCELLATI, C., ROSSONI, G., BONAZZI, A., BERTI, F., MACLOUF, J., FOLCO, G. & SALA, A. (1997). Nitric oxide modulation of transcellular biosynthesis of cys-leukotrienes in rabbit leukocyte-perfused heart. Br. J. Pharmacol., 120, 1128-1134.
2. DELLIPIZZI, A., GUAN, H., TONG, X., TAKIZAWA, H. & NASJLETTI, A. (2000). Lipoxygenase-dependent mechanisms in hypertension. Clin. Exp. Hypertens., 22, 181-192.
3. DIXON, R.A., DIEHL, R.E., OPAS, E., RANDS, E., VICKERS, P.J., EVANS, J.F., GILLARD, J.W. & MILLER, D.K. (1990). Requirement of a 5-Lipoxygenase-activating protein for leukotriene synthesis. Nature, 343, 282-284.
4. FOLCO, G., ROSSONI, G., BUCCELLATI, C., BERTI, F., MACLOUF, J. & SALA, A. (2000). Leukotrienes in cardiovascular diseases. Am. J. Respir. Crit. Care Med., 161, S112-S116.
5. GONZALEZ-NUNEZ, D., CLARIA, J., RIVERA, F. & POCH. E. (2001). Increased levels of 12(S)-HETE in patients with essential hypertension. Hypertension, 37, 334-338.
6. HEISE, C.E., O'DOWD, B.F., FIGUEROA, D.J., SAWYER, N., NGUYEN, T., IM, D.S., STOCCO, R., BELLEFEUILLE, J.N., ABRAMOVITZ, M., CHENG, R., WILLIAMS, JR, D.L., ZENG, Z., LIU, Q., MA, L., CLEMENTS, M.K., COULOMBE, N., LIU, Y., AUSTIN, C.P., GEORGE, S.R., O'NEILL, G.P., METTERS, K.M., LYNCH, K.R. & EVANS, J.F. (2000). Characterization of the human cysteinyl leukotriene 2 receptor. J. Biol. Chem., 275, 30531-30536.
7. HENRION, D., DOWELL, F.J., LEVY, B.I. & MICHEL, J.B. (1996). In vitro alteration of aortic vascular reactivity in hypertension induced by chronic NG-nitro-L-arginine methyl ester. Hypertension, 28, 361-366.
8. KATOH, M., EGASHIRA, K., USUI, M., ICHIKI, T., TOMITA, H., SHIMOKAWA, H., RAKUGI, H. & TAKESHITA, A. (1998). Cardiac angiotensin II receptors are upregulated by long-term inhibition of nitric oxide synthesis in rats. Circ. Res., 83, 743-751.
9. KERTTULA, T., RIUTTA, A., KAUKINEN, S., METSA-KETELA, T., SEPPALA, E., VAPAATALO, H. & ALANKO, J. (1995). Noradrenaline and dopamine infusions modulate arachidonic acid cyclooxygenase and 5-lipoxygenase pathways ex vivo in man. Prostagland. Leukotr. Essent. Fatty Acids, 53, 47-52.
10. LABELLE, E.F. & POLYAK, E. (1998). Norepinephrine stimulates arachidonic acid release from vascular smooth muscle via activation of cPLA2. Am. J. Physiol., 274, C1129-C1137.
11. LAWSON, D.L., SMITH, C., MEHTA, J.L., MEHTA, P. & NICHOLS, W.W. (1988). Leukotriene D4 potentiates the contractile effects of epinephrine and norepinephrine on rat aortic rings. J. Pharmacol. Exp. Ther., 247, 953-957.
12. LYNCH, K.R., O'NEILL, G.P., LIU, Q., IM, D.S., SAWYER, N., METTERS, K.M., COULOMBE, N., ABRAMOVITZ, M., FIGUEROA, D.J., ZENG, Z., CONNOLLY, B.M., BAI, C., AUSTIN, C.P., CHATEAUNEUF, A., STOCCO, R., GREIG, G.M., KARGMAN, S., HOOKS, S.B., HOSFIELD, E., WILLIAMS, JR, D.L., FORD-HUTCHINSON, A.W., CASKEY, C.T. & EVANS, J.F. (1999). Characterization of the human cysteinyl leukotriene CysLT1 receptor. Nature, 399, 789-793.
13. MAZZETTI, L., FRANCHI-MICHELI, S., NISTRI, S., QUATTRONE, S., SIMONE, R., CIUFFI, M., ZILLETTI, L. & FAILLI, P. (2003). The ACh-induced contraction in rat aortas is mediated by the Cys Lt(1) receptor via intracellular calcium mobilization in smooth muscle cells. Br. J. Pharmacol., 138, 707-715.
14. NASJLETTI, A. (1998). Arthur C. Corcoran Memorial Lecture. The role of eicosanoids in angiotensin-dependent hypertension. Hypertension, 31, 194-200.
15. NOTHACKER, H.P., WANG, Z., ZHU, Y., REINSCHEID, R.K., LIN, S.H. & CIVELLI, O. (2000). Molecular cloning and characterization of a second human cysteinyl leukotriene receptor: discovery of a subtype selective agonist. Mol. Pharmacol., 58, 1601-1608.
16. NOZAWA, K, TUCK, M.L., GOLUB, M., EGGENA, P., NADLER, J.L. & STERN, N. (1990). Inhibition of lipoxygenase pathway reduces blood pressure in renovascular hypertensive rats. Am. J. Physiol., 259, H1774-H1780.
17. 4 are potent endothelium-dependent relaxing agents in canine splanchnic venous capacitance vessels. Circ. Res., 73, 395-404.
18. PETERS-GOLDEN, M. & BROCK, T.G. (2001). Intracellular compartmentalization of leukotriene synthesis: unexpected nuclear secrets. FEBS Lett., 487, 323-326.
19. PROVOST, P., BORGEAT, P. & MERHI, Y. (1998). Platelets, neutrophils, and vasoconstriction after arterial injury by angioplasty in pigs: effects of MK-886, a leukotriene biosynthesis inhibitor. Br. J. Pharmacol., 123, 251-258.
20. RAYCHAUDHURI, A., CHERTOCK, H., PEPPARD, J., WHITE, W.D., KOELER, J. & DIPASQUALE, G. (1993). Effect of 5-lipoxygenase inhibitors on in situ LTB4 biosynthesis following calcium ionophore stimulation in the rat pleural cavity. Agents Actions, 39, C43-C45.
21. ROUZER, C.A., FORD-HUTCHINSON, A.W., MORTON, H.E. & GILLARD, J.W. (1990). MK886, a potent and specific leukotriene biosynthesis inhibitor blocks and reverses the membrane association of 5-lipoxygenase in ionophore-challenged leukocytes. J. Biol. Chem., 265, 1436-1442.
22. ROUZER, C.A. & KARGMAN, S. (1988). Translocation of 5-lipoxygenase to the membrane in human leukocytes challenged with ionophore A23187. J. Biol. Chem., 263, 10980-10988.
23. SALA, A. & FOLCO, G. (2001). Neutrophils, endothelial cells, and cysteinyl leukotrienes: a new approach to neutrophil-dependent inflammation? Biochem. Biophys. Res. Commun., 283, 1003-1006.
24. SALAS, A., PANES, J., ELIZALDE, J.I., CASADEVALL, M., ANDERSON, D.C., GRANGER, D.N. & PIQUE, J.M. (1998). Mechanisms responsible for enhanced inflammatory response to ischemia-reperfusion in diabetes. Am. J. Physiol., 275, H1773-H1781.
25. + currents in rat arterial myocytes. Br. J. Pharmacol., 124, 572-578.
26. STANKE-LABESQUE, F., DEVILLIER, P., VEITL, S., CARON, F., CRACOWSKI, J.L. & BESSARD, G. (2001). Cysteinyl leukotrienes are involved in angiotensin II-induced contraction of aorta from spontaneously hypertensive rats. Cardiovasc. Res., 49, 152-160.
27. STANKE-LABESQUE, F., HARDY, G., VERGNAUD, S., DEVILLIER, P., PEOC'H, M., RANDON, J., BRICCA, G., CARON, F., CRACOWSKI, J.L. & BESSARD, G. (2002). Involvement of cysteinyl leukotrienes in angiotensin II-induced contraction in isolated aortas from transgenic (mRen-2)27 rats. J. Hypertens., 20, 263-272.
28. STEINHILBER, D. (1999). 5-Lipoxygenase: a target for antiinflammatory drugs revisited. Curr. Med. Chem., 6, 71-85.
29. STERN, N., NOZAWA, K., GOLUB, M., EGGENA, P., KNOLL, E. & TUCK, M.L. (1993). The lipoxygenase inhibitor phenidone is a potent hypotensive agent in the spontaneously hypertensive rat. Am. J. Hypertens., 6, 52-58.
30. TOMITA, H., EGASHIRA, K., KUBO-INOUE, M., USUI, M., KOYANAGI, M., SHIMOKAWA, H., TAKEYA, M., YOSHIMURA, T. & TAKESHITA, A. (1998). Inhibition of NO synthesis induces inflammatory changes and monocyte chemoattractant protein-1 expression in rat hearts and vessels. Arterioscler. Thromb. Vasc. Biol., 18, 1456-1464.
31. USUI, M., EGASHIRA, K., TOMITA, H., KOYANAGI, M., KATOH, M., SHIMOKAWA, H., TAKEYA, M., YOSHIMURA, T., MATSUSHIMA, K. & TAKESHITA, A. (2000). Important role of local angiotensin II activity mediated via type 1 receptor in the pathogenesis of cardiovascular inflammatory changes induced by chronic blockade of nitric oxide synthesis in rats. Circulation, 101, 305-310.
32. WALCH, L., NOREL, X., GASCARD, J.P. & BRINK, C. (2000). Functional studies of leukotriene receptors in vascular tissues. Am. J. Respir. Crit. Care Med., 161, S107-S111.
33. WANGENSTEEN, R., O'VALLE, F., DEL MORAL, R., VARGAS, F. & OSUNA, A. (2002). Chronic alpha1-adrenergic blockade improves hypertension and renal injury in L-NAME and low-renin L-NAME-DOCA hypertensive rats. Med. Sci. Monit., 8, BR378-BR384.